A combination of DCsEVs and ICBs (anti-CTLA-4 therapy or PD-1/PD-L1 blockade) may further enhance the cross-priming of CD8+ T cells and alleviate the suppression of tumor-infiltrating CTLs [304,325]. Here, PDCD1 is linked to neoplasm.